Bisphosphonates and Risk of Upper Gastrointestinal Cancer - A Case Control Study Using the General Practice Research Database (GPRD)

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wright, Ellen ^a   Schofield, Peter T ^a   Seed, Paul ^a   Molokhia, Mariam ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DATA BASE; DIGESTIVE SYSTEM CANCER; DYSPEPSIA; ELECTRONIC MEDICAL RECORD; ESOPHAGUS CANCER; FEMALE; GENERAL PRACTICE RESEARCH DATABASE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; STOMACH CANCER; UNITED KINGDOM; UPPER GASTROINTESTINAL TRACT;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTESTINES; MALE; MIDDLE AGED; RISK FACTORS; STOMACH;

EID: 84868091793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047616     Document Type: Article

References (25)

1. Watson J, Wise L, Green J, (2007) Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63: 843-849.
2. Parfitt JR, Driman DK, (2007) Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 38: 527-536.
3. Wysowski DK, (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 89-90.
4. Wysowski DK (2010) Oral bisphosphonates and oesophageal cancer. BMJ 341.
5. Abrahamsen B, Eiken P, Eastell R (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 1789; author reply 1791-1782.
6. Solomon DH, Patrick A, Brookhart MA (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 1789-1790; author reply 1791-1782.
7. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ, (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304: 657-663.
8. Green J, Czanner G, Reeves G, Watson J, Wise L, et al. (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341: c4444.
9. Dixon WG, Solomon DH, (2011) Bisphosphonates and esophageal cancer-a pathway through the confusion. Nat Rev Rheumatol 7: 369-372.
10. Haber SL, McNatty D, (2012) An Evaluation of the Use of Oral Bisphosphonates and Risk of Esophageal Cancer. The Annals of Pharmacotherapy 46: 419-423.
11. Nguyen D, Schwartz J, Richardson P, El-Serag H, (2010) Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus. Digestive Diseases and Sciences 55: 3404-3407.
12. GPRD (2010) The Database.
13. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ, (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69: 4-14.
14. Khan NF, Harrison SE, Rose PW, (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60: e128-136.
15. CancerResearchUK Cancer Statistics.
16. Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R (2011) Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res.
17. Vestergaard P, (2011) Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 89: 434-441.
18. Chen Y-M, Tsai Y-W, Liu C-L, Chen Y-T, Chang L-C, et al. (2011) Alendronate and Risk of Esophageal Cancer: A Nationwide Population-Based Study in Taiwan.
19. Ho YF, Lin JT, Wu CY, (2012) Oral bisphosphonates and risk of esophageal cancer: a dose-intensity analysis in a nationwide population. Cancer Epidemiol Biomarkers Prev 21: 993-995.
20. Altman D (1991) Practical Statistics in Medical Research.[16.4.3 Errors in Analysis]. London: Chapman & Hall.
21. Colina RE, Smith M, Kikendall JW, Wong RK, (1997) A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol 92: 704-706.
22. Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, et al. (2002) 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 29: 1965-1974.
23. Zhang J, Yun H, Wright NC, Kilgore M, Saag KG, et al. (2011) Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies. Curr Rheumatol Rep 13: 273-282.
24. Walker AM, (2011) Identification of esophageal cancer in the General Practice Research Database. Pharmacoepidemiology and Drug Safety 20: 1159-1167.
25. Vinogradova Y, Coupland C, Hippisley-Cox J (2012) Exposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database. BMJ Open 2.